A no rexia ner vosa (AN), bu li mia ner vosa (BN), and binge eat ing dis or der (BED) are se ri ous con di tions that im pair both psy cho logi cal and physi cal health. More preva lent in indus tri al ized na tions, these ill nesses af fect all so cio eco nomic classes of every eth nic ity in North Amer ica (1). Eat ing dis orders (EDs) af fect pri mar ily women, with only 5% to 15% of AN and BN pa tients and 40% of BED pa tients be ing boys or men (2,3). Three per cent of women will be af fected by EDs over their life time (4). Col lec tively, EDs are char ac ter ized by se vere dis tur bances in eat ing be hav iour as well as dis tress over body shape and weight.
Treat ment of AN is chal leng ing and usu ally in volves a mul tidis ci plin ary ap proach. Se ri ously un der weight pa tients are best ad mit ted to a hos pi tal or day pro gram where they can receive psy cho logi cal coun sel ling with cognitive-behavioural com po nents, nu tri tional edu ca tion, and a diet en sur ing 2000 to 4000 calo ries daily. Weight gain is es sen tial for AN treat ment to be mean ing ful. Al though phar ma co ther apy is a fre quent adjunc tive in ter ven tion, there is scant evi dence for its ef fec tiveness. An im pres sive phar ma co poeia has been ex am ined, mainly for the acute phase of AN, with only iso lated and of ten in con sis tent suc cesses. An tipsy chot ics and lith ium were first stud ied, to take ad van tage of their weight-gain side ef fect. Anti de pres sants were in ves ti gated be cause of the noted as so ciation be tween AN and de pres sive symp toms. It was hoped that proki netic agents could aug ment weight gain by di rect physiologi cal ef fects, and zinc piqued cu ri os ity be cause the clini cal fea tures of zinc de fi ciency in some ways re sem ble AN.
An tipsy chot ics
The an tipsy chotic chlor pro maz ine was first stud ied in the 1960s (6, 7) . Al though they achieved ini tial weight gain, patients also suf fered con sid er able side ef fects, in clud ing grand mal sei zures and in creased purg ing. On long-term study, chlor pro maz ine yielded no greater weight gain than that noted in his tori cal con trol groups. Other do pa mine an tago nists were ex am ined in double-blind placebo-controlled stud ies (pimozide [8] and sul piride [9] ). While pi mozide re sulted in some weight gain over pla cebo, sul piride pro vided no sig nificant bene fit. Nei ther agent im proved pa tients' at ti tudes or be hav iours.
Given the sub stan tial side-effect pro file of tra di tional an tipsychotic drugs and the scant evi dence of their ef fec tive ness, there has been lit tle rea son to con sider their rou tine use in treat ing AN. How ever, the ar ri val in the last dec ade of novel an tipsy chotic medi ca tions with a much more fa vour able side-effect pro file has re kin dled in ter est in a pos si ble role for this class of drugs. In par ticu lar, re cent case study re ports have de scribed ol an zap ine as use ful for the treat ment of AN (10, 11) . These 2 stud ies chose to ex am ine ol an zap ine both because of its an tipsy chotic ef fects (con cep tu al iz ing the bi zarre body im age in AN as a form of psy cho sis) and be cause of the im pres sive weight gain as so ci ated with its use. Both case stud ies re ported dra matic im prove ments in their sub jects, mer it ing fur ther, con trolled ex ami na tion of the drug's util ity.
Lith ium
Like an tipsy chotic medi ca tions, lith ium is also as so ci ated with weight gain. A placebo-controlled study showed this mood sta bi lizer to be as so ci ated with a small weight in crease in AN pa tients, but the study was lim ited by its small sam ple size and short du ra tion (12) .
An ti de pres sants
The use of an ti de pres sants in AN man age ment was a logi cal choice, given that many pa tients with AN also suf fer from depres sive symp toms, in clud ing de pressed mood, low en ergy, loss of in ter est, and so cial iso la tion. At first, it was hoped that the weight-gain side ef fect of tri cyc lic an ti de pres sants (TCAs) would fur ther aug ment their an ti de pres sant prop er ties and im prove out come. Clo mi pramine was found to in crease ap pe tite, but weight gain on long-term follow-up at 1 and 4 years proved dis ap point ing (13) . Like wise, tri als of amitriptyline dem on strated nei ther in creased weight nor re duced con cerns re gard ing shape and weight (14, 15) . Re cent data on the link be tween TCAs and sud den death in young peo ple (16) , cou pled with the in creased pro pen sity for car diac arrhyth mias at low body weight, pro vide ad di tional con tra in dica tions for the use of TCAs in AN treat ment.
In more re cent years the se lec tive se ro tonin re up take in hibitors (SSRIs), a class of an ti de pres sant medi ca tion with a much more be nign side-effect pro file, have been in ves ti gated. Open tri als of fluoxet ine in small sam ples of acutely ill pa tients suggested that fluoxet ine might re sult in weight gain and improved mood (17, 18) . A placebo-controlled trial, how ever, showed that fluoxet ine con ferred no sig nifi cant bene fits over pla cebo in the treat ment of women hos pi tal ized for AN (19) . Some what more en cour ag ing data have emerged from a study of fluoxet ine used to pre vent re lapse fol low ing weight gain. Kaye and co work ers as signed women with AN who had achieved near-normal weight af ter in pa tient hos pi tali za tion to fluoxet ine or pla cebo; they found that those who re ceived fluoxet ine had a sig nifi cantly lower rate of re lapse than those who re ceived pla cebo (20) . In a natu ral is tic case-control follow-up study, how ever, Strober and col leagues found no dif fer ence on meas ures of need for re hos pi tali za tion and tendency to drop be low tar get weight (21) . The re search on an tide pres sants in AN is there fore gen er ally dis ap point ing, with no evi dence that such agents are use ful for un der weight patients. The no tion that SSRIs may help to pre vent re lapse among pa tients who have re gained weight is in trigu ing and should be stud ied fur ther.
Cy pro hep tadine
The se ro tonin an tago nist cy pro hep tadine has been ex am ined in sev eral con trolled stud ies. That this agent is thought to have neu ro chemi cal ef fects op po site to those of the SSRIs is a no table il lus tra tion of the fact that at tempted phar ma cologic in terven tions for AN are not based on an un der stand ing of un der ly ing pa tho physi ol ogy. Cy pro hep tadine is an an ti his tamine that de creases cen tral se ro tonin ac tiv ity and was noted to cause weight gain when used in the treat ment of al ler gic pru ri tus. One placebo-controlled study of pa tients with AN showed no sig nifi cant im prove ment with cy pro hep tadine (22) . How ever, in an other study that used a larger sam ple size and a higher dos age, the drug in duced a sig nifi cant weightgain ef fect, al though only in pa tients with the more se vere form of the ill ness (23) . Some what dif fer ent re sults emerged from a third trial wherein a dif fer en tial ef fect was found based on sub type, such that cry pro hep tadine en hanced weight gain in the re strict ing sub group but slowed weight gain in the binge and purge sub group (15) . Al though this evi dence sug gests that sub types of AN re spond dif fer ently to modi fi ca tions of se ro to ner gic trans mis sion, the ef fects of cy pro hep tadine were small, and this agent is not widely used in AN treat ment.
Tet ra hy dro can nabi nol
Given the appetite-stimulating and an tie metic prop er ties of tet ra hy dro can nabi nol (THC), much re search has fo cused on its role in can cer che mo ther apy. THC was also ex am ined in pa tients with AN, but re sults were dis ap point ing. In a 4-week, double-blind cross over study of 11 pa tients that com pared oral THC to di aze pam, no sig nifi cant ef fect was found on food in take or weight gain (24) . Pa tients re ceiv ing THC did, however, ex pe ri ence nega tive side ef fects, in clud ing sleep dis turbance and in ter per sonal sen si tiv ity. A few pa tients dropped out of the study due to dys pho ria, para noia, and a feel ing of be ing out of con trol.
Cisa pride
Some work has also been aimed at re vers ing the physio logi cal dis tur bances as so ci ated with AN. Pa tients with AN fre quently com plain of so matic symp toms such as gas tric full ness and bloat ing. Cisa pride, a proki netic agent, was pro posed as a ther apy to re lieve these gas tro in tes ti nal symp toms and thereby in crease food in take. Stacher and co work ers measured gas tric emp ty ing, gas tric com plaints, and weight gain in hos pi tal ized pa tients and found an im prove ment in symp toms in those re ceiv ing the ac tive drug. How ever, the dif fer ence was not sig nifi cant (25) . A more re cent ran dom ized con trolled study with a larger sam ple size found no sig nifi cant dif fer ence in gas tric emp ty ing time or weight gain be tween cisa pride and pla cebo (26) . Fur ther, since that trial, cisa pride has been withdrawn from the mar ket be cause of rare but po ten tially fa tal car diac ef fects. Zinc Like pa tients with AN, in di vidu als with zinc de fi ciency may ex hibit weight loss, ap pe tite and taste changes, de pres sion, and ame nor rhea. These simi lari ties sug gested that a dietaryinduced zinc de fi ciency might con trib ute to the psy cho pa thology of AN, per haps in di cat ing a role for zinc sup ple men ta tion. Early case re ports showed mixed re sults (27) (28) (29) (30) . Three double-blind placebo-controlled tri als of zinc have been pub lished to date. Katz and co work ers re ported that zinc supple men ta tion de creased anxi ety and de pres sive symp toms in ado les cents with AN but had no ef fect on weight gain (31) . In a study of adult fe male in pa tients ran dom ized to re ceive zinc glu co nate or pla cebo, sup ple men ta tion re sulted in a faster increase in body mass in dex (BMI) (32) . Con versely, Lask and co work ers found no bene fit in pa tients with childhood-onset AN who re ceived zinc sul fate in a double-blind placebocontrolled trial (33) . Thus, the role of zinc de fi ciency in AN is still un cer tain, and zinc sup ple men ta tion is not well sup ported by the lit era ture at this time.
Com ments
The ab sence of suc cess ful psy cho phar ma co logi cal ther apy for AN is per plex ing. Why are the ef fects of medi ca tion so lim ited, de spite the many symp toms shared by AN and other psy chi at ric ill nesses such as de pres sion, ob ses sive-com pulsive dis or der (OCD), and BN, which are medi ca tion re sponsive? The lack of an ani mal model ham pers both the search for novel thera peu tic agents and an un der stand ing of the un der lying neu ro bio logic dys func tion lead ing to ano rexia. It seems less than ideal to search for treat ments for a dis or der by choosing drugs on the ba sis of their side-effects. None the less, the en cour ag ing case re ports re gard ing ol an zap ine are wor thy of rep li ca tion and ex ten sion in double-blind tri als.
In ad di tion, the re cent fo cus on phar ma cologic in ter ven tion to re duce re lapse af ter weight gain holds prom ise. If con trolled tri als con vinc ingly dem on strate medi ca tion to be help ful at this stage of ill ness, we will fi nally have a bio logi cal in ter vention (other than weight gain) that is of bene fit. Lastly, the utility of a medi ca tion in normal-weight, but not in un der weight pa tients, strongly sug gests that the neu ro chemi cal ef fects of star va tion play a ma jor role in treat ment re sponse.
Bu li mia Ner vosa
BN, which strikes be tween 1% and 3% of ado les cent and young adult fe males (34, 35) , is a dis or der char ac ter ized by epi sodes of binge eat ing large amounts of food ac com pa nied by in ap pro pri ate com pen sa tory at tempts and a sense of loss of con trol. The DMS-IV sub di vides BN pa tients into 2 types: those who purge by self-induced vom it ing or the use of laxatives or diu ret ics and those who do not purge but, in stead, engage in ex ces sive ex er cise or fast ing.
Be cause of BN's higher preva lence, com pared with AN, and be cause pa tients can usu ally be man aged in an out pa tient setting, treat ment stud ies of BN have been eas ier to con duct and are more nu mer ous than those of AN. For this rea son, and possi bly be cause BN is not as so ci ated with the pro found, starvation-induced physio logi cal ab er ra tions char ac ter is tic of AN, ef fec tive ther apy for BN has seen con sid er able prog ress, when com pared with AN. Most phar ma cologic stud ies of BN have fo cused on the use of an ti de pres sants, in part be cause of comor bid de pres sive symp toms of ten ob served in BN patients, and in part be cause of the suc cess of early an ti de pressant tri als. In ad di tion, tri als of an ti con vul sants, se ro to ner gic ago nists, opi ate an tago nists, and lith ium have been re ported, al though they of ten show less ro bust ef fi cacy than do an ti depres sants. New agents mer it ing fur ther study are topi ra mate (sug gested by a re cent case study) and on dan setron (sup ported by a double-blind, placebo-controlled study). Fi nally, because of the util ity of cognitive-behavioural ther apy (CBT) in the treat ment of BN, sev eral phar ma co ther apy and psy chother apy combined-treatment para digms have been ex am ined, with some what in con sis tent re sults.
An ti de pres sants
A large number of stud ies us ing vari ous an ti de pres sants for BN, and show ing roughly equal ef fi cacy, have been pub lished (36, 37) . The SSRI fluoxet ine has re ceived the most at ten tion and has been ap proved by the US Food and Drug Ad min istration for the treat ment of BN in adults. One large mul ti cen tre trial com pared pa tient re sponse to pla cebo and to 20 mg fluoxet ine or 60 mg fluoxet ine daily and found only the higher dos age to be clearly su pe rior to pla cebo (38) . In ad di tion to im prov ing char ac ter is tic symp toms of BN, such as binge eating, purg ing, and con cerns about weight or body shape, fluoxet ine also de creases de pres sive and anxi ety symp toms.
De spite good re sponse rates dur ing short-term treat ment with an ti de pres sants, few stud ies have re ported suc cess ful longterm out come. The over whelm ing fo cus on short-term re sults thus leaves open many key ques tions re gard ing long-term strate gies in par ticu lar, how they may dif fer from those success ful in the short term. In ad di tion, most stud ies ex am ined adult fe male pa tients with the purg ing sub type of BN, which re quires cli ni cians to ex trapo late these data to the treat ment of the non purging sub type and of younger pa tients.
An ti con vul sants
Small stud ies of the an ti con vul sants pheny toin (39) and car bamazepine (40) showed mini mal ef fects in a small number of pa tients. Within the last few years, the an ti con vul sant topi ramate has emerged as an agent re quir ing greater study for the treat ment of BN. Knable pub lished a case re port of a pa tient with epi lepsy and comor bid BN, with the clini cal pres en ta tion of the lat ter pre dat ing the former (48). A 5-year course of pheny toin ame lio rated the epi lepsy in this pa tient but did not al ter her binge eat ing or purg ing be hav iours. How ever, switch ing the pa tient to topi ra mate, an an ti con vul sant with pur ported ac tion at voltage-gated so dium chan nels, GABA recep tors, and glu ta mate re cep tors pow er fully de creased her con vul sions and auras; it also de creased her con cern about weight and her de sire for binge eat ing, purg ing, and selfmutilation. Larger con trolled stud ies are nec es sary to ex plore the prom ise of topi ra mate for BN.
On dan setron
A novel ap proach to phar ma co ther apy of BN has re cently come from re ports by Fa ris and col leagues. Prior stud ies have dem on strated that pa tients with BN re quire more food to reach full ness and have dif fi culty ter mi nat ing meals, sug gest ing a defi cit in nor mal sa ti ety (49) . Pre ab sorp tive fac tors, like ac tiva tion of vis ceral va gal nerve af fer ents, play a cen tral role in the sa ti ety pro cess. Fa ris and oth ers hy pothe sized that an increase in va gal nerve ac tiv ity, pos si bly due to over stimu la tion re lated to the cy cles of binge eat ing and purg ing, might lead to de creased sen si tiv ity of va gal af fer ents to food in take. Con sistent with this model, they found that pa tients with BN displayed an in creased so ma to sen sory pain thresh old as a func tion of time since the last bu limic epi sode (50) . Pain thresh old can be modu lated by va gal nerve stimu la tion and thus may in di rectly re flect va gal ac tiv ity. Ad min istra tion of on dan setron, an in hibi tor of the 5-HT 3 re cep tors in volved in vis ceral stimu la tion of va gal af fer ents, elimi nated these cy clic changes in pain thresh old.
A ran dom ized double-blind placebo-controlled study ex amined the ef fect of a 4-week course of on dan setron on eat ing behav iours in pa tients with BN (51) . Pa tients treated with on dan setron showed a 50% de crease in binge-purge epi sodes, a 50% de crease in time spent in binge-purge ac tiv ity, and a 33% in crease in the number of meals not fol lowed by purg ing. The authors did not re port on dan setron's ef fect on such psycho pa thologi cal fea tures of BN as dis torted body im age. None the less, these stud ies pro vide hope for a new di rec tion in BN phar ma co ther apy; that is, us ing drugs that more se lectively tar get the pe riph eral nerv ous sys tem.
Other Medi ca tions
Sev eral con trolled tri als of other agents have been pub lished. With only 1 ex cep tion (41), re sults of tri als us ing the se ro toner gic pre cur sor L-tryptophan (42) and the se ro to ner gic agonist dex fen flu ramine (43, 44) were not im pres sive. (Dex fen flu ramine has since been with drawn from the mar ket be cause of heart-valve ab nor mali ties as so ci ated with its use to treat obe sity.) Like wise, 2 placebo-controlled stud ies us ing the opi ate an tago nist naltrex one failed to find that naltrex one had an ef fect, com pared with pla cebo, in de creas ing binge frequency (45, 46) . Lastly, Hsu and oth ers in ves ti gated the util ity of lith ium vs pla cebo in an 8-week study and found that, while binge fre quency de clined, there was no evi dence that the outcome in the lith ium group was su pe rior to that in the pla cebo group (47) .
Medi ca tion and Psy cho ther apy
In ad di tion to the con sis tent and proven ef fi cacy of an ti de pressant ther apy for short-term treat ment of BN, much work has sup ported a bene fi cial role for psy cho ther apy, par ticu larly CBT in BN treat ment (52) . Sev eral stud ies have in ves ti gated the com bi na tion of phar ma co ther apy and psy cho ther apy. These stud ies used vari ous an ti de pres sants and psy cho therapeu tic mo dali ties, rang ing from nu tri tional coun sel ling to group and in di vid ual psy cho ther apy (53) (54) (55) (56) (57) (58) (59) . Gen er ally, CBT was found to be more ef fec tive than an ti de pres sant medi cation, and the com bi na tion of the 2 was su pe rior to medi ca tion alone. How ever, it is less clear how much bene fit is de rived from add ing medi ca tion to ef fec tive psy cho logi cal treat ment. Re ports us ing TCAs sug gest that, even if add ing an ti de pressants to psy cho ther apy does not fur ther re duce binge eat ing or purg ing, the com bi na tion does im prove symp toms such as anxi ety, de pressed mood, and die tary re stric tion (53, 55) . More re cently, our group com pared CBT with in di vid ual suppor tive psy cho ther apy; we also com pared the ef fect of combin ing medi ca tion with ei ther form of psy cho ther apy (59) . CBT was su pe rior to sup por tive psy cho ther apy, a find ing consis tent with prior find ings on CBT. Add ing an ti de pres sants en hanced the ef fect of both CBT and sup por tive psy cho therapy on binge eat ing and de pres sive symp toms. In ter est ingly, medi ca tion com bined with CBT was su pe rior to medi ca tion alone, but medi ca tion com bined with sup por tive psy cho therapy was not.
It is of note that long-term bene fits of short-term treat ment pro to cols have been dem on strated only for psy cho ther apy and not for medi ca tion alone. Long-term data on the 2 treat ments com bined are lim ited. None the less, there are sev eral al ready well-established treat ment mo dali ties for the short-term treatment of BN, which gives cli ni cians op tions not yet avail able with AN.
Binge Eat ing Dis or der
BED is char ac ter ized by symp toms on 3 di men sions. Be haviour ally, pa tients binge eat but do not use com pen sa tory measures like purg ing or ex ces sive ex er cise. Psy cho logi cally, pa tients are con cerned about body im age and of ten meet cri teria for comor bid anxi ety and de pres sive dis or ders. So matically, BED is char ac ter ized by obe sity, al though this is not for mally re quired for a di ag no sis of BED. In fact, obese binge eat ers com prise 25% to 30% of the obese popu la tion (45) . Thus, treat ment can be tar geted at the psy cho logi cal symptoms of BED, the be hav ioural mani fes ta tions of BED, or in many cases, the obe sity. Treat ment stud ies have sug gested dis so cia tions be tween weight and be hav ioural out comes, with im prove ments in binge eat ing, but with out con comi tant weight loss. Phar ma cologic tri als for BED have ex am ined anti de pres sants, ap pe tite sup pres sants, naltrex one, and topi ra mate. In ad di tion, ef forts ex am in ing com bined medi cation and psy cho ther apy ap proaches are in creas ing.
An ti de pres sants
Be cause of the sub stan tial over lap of symp toms be tween BED and BN, much of the psy cho phar ma co logi cal in ves ti ga tion of BED has fo cused on drugs ef fec tive for BN (pri mar ily, an ti depres sants). In a double-blind placebo-controlled ex ami na tion of non purg ing bu li mia patients, McCann and Agras found that binge fre quency less ened af ter short-term treat ment with the TCA de si pramine (60) . Sub jects re lapsed, how ever, when medi ca tion was dis con tin ued. No sig nifi cant change in weight was seen with medi ca tion, nor were de pres sive symp toms ame lio rated.
A more re cent mul ti cen tre double-blind placebo-controlled study ex am ined the ef fi cacy of the SSRI fluvox am ine (61) . Af ter a 9-week course, the re search ers found a greater re duction in binge fre quency, BMI, and clini cal Global Im pres sion Scale-Severity (CGI-S) scores in the drug-treated group, compared with the pla cebo group. McEl roy and oth ers found similar re sults in a double-blind placebo-controlled trial of the SSRI ser tra line (62) . Both stud ies re ported sta tis ti cally signifi cant weight loss with SSRI treat ment, com pared with placebo. These stud ies sug gest a po ten tial role for SSRIs in the short-term treat ment of BED, but they give no long-term follow-up re sults.
As il lus trated, the fo cus on the short-term ef fec tive ness of drug ther apy has been a con sis tent prob lem for many of the prom is ing stud ies on BED. Fur ther, the ob ser va tions that the bene fi cial ef fects of medi ca tion do not ap pear to per sist follow ing drug dis con tinua tion are dis ap point ing. It is pos si ble that any mean ing ful phar ma cologic treat ment will have to be con tin ued in defi nitely.
Naltrex one
Sev eral stud ies have sug gested that 2 new drugs, naltrex one and topi ra mate, have po ten tial bene fits for the be hav ioural and psy cho logi cal symp toms of BED. Naltrex one is an opi ate an tago nist used to treat al co hol ism. It has also re ceived at tention for the treat ment of bu li mia. Al ger and col leagues compared the ef fects of imi pramine with those of naltrex one and pla cebo in obese BED suf fer ers (45) . They found that both drugs sig nifi cantly re duced binge fre quency but that this improve ment did not dif fer from pla cebo.
Topi ra mate
As with BN, there are sug ges tions that topi ra mate may be useful in the treat ment of BED. In a natu ral is tic, open-label study, Shapira and col leagues re ported that topi ra mate ad mini stration re sulted in a dosage-dependent weight de crease for 13 BED pa tients with comor bid Axis I dis or ders (63) . Ap po linario and oth ers re ported the case of a BED pa tient who re sponded to topi ra mate af ter fail ing sev eral other treat ment mo dali ties (64) . The pa tient showed dra matic im prove ment, fur ther build ing the case for topi ra mate ther apy in BED. Since these new drug tri als are un con trolled, con clu sions will be diffi cult un til large-sample placebo-controlled tri als have been con ducted.
Dex fen flu ramine
Early stud ies showed prom ise for the ap pe tite sup pres sant dex fen flu ramine, but it has since been with drawn from the mar ket be cause of its as so cia tion with heart valve de fects. One study showed short-term binge sup pres sion but post discon tinua tion re lapse (65) . The com bi na tion of appetitesuppressing phen ter mine resin and dex fen flu ramine, popularly known as Phen-Fen, was ex am ined for its ef fect on severely and mod er ately obese binge eat ers, as well as on obese non-binge eat ers (66) . Most sub jects in all 3 groups ex pe rienced a more than 10% weight loss af ter the 6-month course of the medi ca tions. At base line, Beck De pres sion In ven tory (BDI) scores were sig nifi cantly higher in the se vere binge eater group, com pared with non-binge eat ers. These scores im proved un til, at 6 months, no dif fer ence was seen be tween the 2 groups. Rat ings of binge eat ing be hav iour se ver ity, as assessed by the Binge Eat ing Scale, also im proved in all groups over the 6-month pe riod. Echo car dio grams taken dur ing this study also found that a large pro por tion of pa tients dis played evi dence of val vu lar dys func tion, which con firmed the dangers of dex fen flu ramine treat ment. None the less, these re sults sug gest that medi ca tions which re duce weight by sup press ing ap pe tite may be a use ful phar ma cologic in ter ven tion for BED.
Sibu tra mine
A 12-week open trial of the weight loss agent sibu tra mine in 7 obese pa tients with BED has re cently been re ported (67) . The authors re port a com plete reso lu tion of BED in the 7 pa tients, with no binge eat ing epi sodes, a de crease in the binge eat ing be hav iours, and sta tis ti cally sig nifi cant weight loss. However, the de cline ob served in de pres sive symp toms was not sig nifi cant.
Medi ca tion and Psy cho ther apy
Com bined phar ma co ther apy and psy cho ther apy is a treat ment strat egy re ceiv ing in creas ing at ten tion for BED. Clearly, there could be in creased bene fits here, but such com bi na tions could also yield nega tive ef fects. It is con ceiv able that medi ca tion treat ment, par ticu larly with drugs that pro duce a short-term im prove ment in binge eat ing or lead to weight loss, may hinder pa tients' ac qui si tion of psy cho logi cal tools for long-term man age ment of binge eat ing. Pa tients might at trib ute their improve ment to medi ca tion rather than to their own ef forts, which would even tu ally un der mine long-term im prove ment, es pe cially be cause re lapse ap pears likely af ter dis con tinuation of phar ma co ther apy.
A double-blind placebo-controlled study showed that combined fluoxet ine and be hav ioural ther apy pro duced sig nificantly greater weight loss than did pla cebo and be hav ioural ther apy for both obese binge eat ers and obese non-binge eaters (68) . How ever, the drug did not ap pear to have a dif fer ential bene fit for binge eat ers. In an other study in which pa tients also re ceived 9 months of psy cho logi cal ther apy, de si pramine had no im pact on binge eat ing dur ing or af ter treat ment (69) . The drug-treated pa tients, how ever, showed greater weight loss at follow-up than did pa tients who did not re ceive medica tion. No dif fer ence in de pres sive symp toms was found.
Dev lin and oth ers re ported an un con trolled trial of 16 obese women who re ceived in di vid ual CBT along with phen ter mine and fluoxet ine, fol lowed by a once-monthly main te nance treat ment (70) . At the end of 20 weeks of ac tive treat ment, patients showed a re duc tion in binge fre quency, weight, and psycho logi cal dis tress, al though they re gained much of the lost weight within a year.
In con trast to most phar ma cologic stud ies of ED, LaederachHofman and oth ers re ported that a short course of treat ment with imi pramine had a per sis tent bene fit among pa tients with BED (71). Thirty-one pa tients were as signed to ei ther imipramine (75 mg daily) or pla cebo for 8 weeks, in ad di tion to bi weekly die tary coun sel ling. Af ter 8 weeks, the medi ca tion was dis con tin ued, but pa tients con tin ued to re ceive die tary coun sel ling for an ad di tional 6 months. It ap pears that the patients re ceiv ing imi pramine showed greater im prove ment in weight, de pres sion, and binge fre quency af ter 8 weeks and that the su pe ri or ity as so ci ated with imi pramine per sisted for 6 months af ter the drug was dis con tin ued. While in trigu ing, these data should be viewed cau tiously, as the authors sug gest. The dos age of imi pramine was quite low, and no other study of ED has sug gested that such a short course of medi ca tion has a per sis tent ef fect.
Com ments
Clearly, no route to long-lasting bene fit has been found for BED suf fer ers, al though a number of medi ca tions have been tried and sev eral show prom ise. One of the most dif fi cult prob lems re mains the of ten dra matic short-term ef fect of phar ma co ther apy fol lowed by rapid re lapse upon dis continua tion of treat ment. Per haps a longer course of agents with lower side-effect pro files may prove ul ti mately bene fi cial, or com bi na tions of psy cho ther apy and phar ma co ther apy may allow for syn er gis tic ef fects. Such specu la tions, how ever, are not yet sup ported by data. In ad di tion, the util ity of cer tain classes of drugs (for ex am ple, weight-loss agents such as sibutra mine) are still rela tively un ex plored.
Con clu sion
Over all, this re view of the phar ma cologic treat ment of ED pres ents a very mixed pic ture. For pa tients with BN, an ti depres sant medi ca tion is a well-tested and widely-used treatment op tion. Pro voca tive new ideas, such as the use of topi ra mate and on dan setron, are also be ing ex am ined. For patients with AN, the ab sence of con vinc ingly dem on strated phar ma cologic op tions is quite dis ap point ing, given the se verity of this ill ness and the range of drug treat ments shown to be ef fec tive in re lated dis or ders. New ef forts fo cus ing on re lapse pre ven tion and on the use of novel an tipsy chot ics will, we hope, prove more fruit ful. There is grow ing evi dence that the symp toms of BED are medication-responsive, but the roles of both phar ma co ther apy and psy cho ther apy in the treat ment of this syn drome need fur ther defi ni tion.
